Showing 2181-2190 of 4063 results for "".
- New Evidence Suggests Young Children Spread COVID-19 More Efficiently Than Adultshttps://modernod.com/news/new-evidence-suggests-young-children-spread-covid-19-more-efficiently-than-adults/2478128/Two new studies, though from different parts of the world, have arrived at the same conclusion: that young children not only transmit SARS-CoV-2 efficiently, but may be major drivers of the pandemic as well, according to a Forbes
- Gilead’s Veklury Gains Conditional EU Approval for Treatment of COVID-19https://modernod.com/news/gileads-veklury-gains-conditional-eu-approval-for-treatment-of-covid-19/2477970/Gilead Sciences said Friday that the European Commission granted conditional approval to Veklury (remdesivir) for the treatment of SARS-CoV-2 infection. The company noted that the clearance, which was based on a rolling review that began in April, follows a
- AMA Pushes for Federal Intervention to Reform Prior Authorizationhttps://modernod.com/news/ama-pushes-for-federal-intervention-to-reform-prior-authorization/2477934/Docs say health plans have made little progress toward streamlining prior authorization—despite pledging to do so 2 years ago, according to a FierceHealthcare report.
- Analysis: Ophthalmology Lost More Patient Volume Due to COVID-19 Than Any Other Specialtyhttps://modernod.com/news/analysis-55-percent-fewer-americans-sought-hospital-care-in-march-april-due-to-covid-19/2477738/A new large analysis revealed that ophthalmology lost more patient volume due to the COVID-19 pandemic than any other medical specialty. The analysis of over 2 million patient visits and encounters
- Sanofi/Regeneron and Roche Report Mixed Results for Potential COVID-19 Treatmentshttps://modernod.com/news/sanofi-regeneron-and-roche-report-mixed-results-for-potential-covid-19-treatments/2477661/Sanofi and Regeneron Pharmaceuticals said that preliminary results from the phase 2 portion of an ongoing study showed that the IL-6 receptor antibody Kevzara (sarilumab) had “no notable benefit” on clinical outcomes v
- Orbis International Commences First-Ever Training Program in the United Stateshttps://modernod.com/news/orbis-international-commences-first-ever-training-program-in-the-united-states/2477368/Orbis International commenced its first-ever training program in the United States. Eye care professionals from Latin America have come to Texas for 2 weeks of training on board Orbis’s Flying
- Verana Health Appoints Veteran Cardiologist Matthew Roe, MD, as Chief Medical Officerhttps://modernod.com/news/verana-health-appoints-veteran-cardiologist-matthew-roe-md-as-chief-medical-officer/2477312/Verana Health announced the appointment of Matthew Roe, MD, MHS, as Chief Medical Officer. A cardiologist and clinical researcher, Dr. Roe joins Verana Health after spending over 2 decades at the Duke University Schoo
- Allegro to Present Clinical Research on the Novel Integrin-Regulating Portfolio at AAOhttps://modernod.com/news/allegro-to-present-clinical-research-on-the-novel-integrin-regulating-portfolio-at-aao/2476956/Allegro Ophthalmics announced that the results of its phase 2 clinical study of risuteganib (Luminate) for the treatment of intermediate nonexudative age-related macular degeneration (AMD) will be presented during AAO
- Peripapillary Retinal Nerve Thinning Faster in People With Diabeteshttps://modernod.com/news/peripapillary-retinal-nerve-thinning-faster-in-people-with-diabetes/2476787/People with type 2 diabetes show accelerated thinning of the peripapillary retinal nerve fiber layer (pRNFL), even in the absence of diabetic retinopathy (DR), according to South Korean researchers, Reuters Health reported. “
- Oyster Point Announces Enrollment of First Subject in Phase 3 Clinical Trial of Nasal Spray for Dry Eye Diseasehttps://modernod.com/news/oyster-point-announces-enrollment-of-first-subject-in-phase-3-clinical-trial-of-nasal-spray-for-dry-eye-disease/2476763/Oyster Point Pharma announced enrollment of the first subject in the phase 3 ONSET-2 clinical trial of OC-01 nasal spray for the treatment of the signs and symptoms of dry eye disease. “After successfully compl